Document is current
Any future updates will be listed below
-
Authors
van Akkooi, Alexander https://orcid.org/0000-0002-3262-6935
Ariyan, Charlotte https://orcid.org/0000-0003-0818-3895
Moncrieff, Marc https://orcid.org/0000-0003-4492-235X
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 6 August 2025
First Online: 29 August 2025
Disclosure
: Alexander van Akkooi has received honoraria from, or participated in a consultancy or advisory role for, Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Genmab, Menarini Silicon Biosystems, Merck Serono-Pfizer, MSD Merck, Neracare, Novartis, Pierre Fabre, Provectus, Replimune, Sanofi, Sirius Medical, SkylineDx, and 4SC, and has received research funding from Amgen, Merck Serono–Pfizer, and SkylineDx. Charlotte Ariyan has received support from Iovance Biotherapeutics, Inc., Pfizer, Merck, Bristol Myers Squibb, and is a member of the Advisory Board for Replimune and Mural Oncology. Marc Moncrieff has no disclosures to declare that may be relevant to the contents of this study.
